EUROPE IBS-C DRUG MARKET FORECAST 2017-2025
KEY FINDINGS
The Europe IBS-c drug market is expected to grow at a CAGR of 5.29% over the forecast period of 2017-2025. The market was valued at $468.6 million in the year 2016 and the market worth is set to optimize up to $744.66 million by the end of 2025.
MARKET INSIGHTS
The European market is mainly driven by factors such as unhealthy eating habits, improved and efficient drugs in the pipeline and the easy availability of the drug in the European market. The segmentation of the market is done based on two criteria: drug type and prescription type. Lubiprostone drug is currently the most popular drug in the market. Also, the over the counter drug types are preferred over the branded and generic prescribed drugs. However, the unawareness and ignorance in the general populace regarding the drugs might restrict the market growth in the coming future.
COMPETITIVE INSIGHTS
Some of the major players in the market include:
The Europe IBS-c drug market is expected to grow at a CAGR of 5.29% over the forecast period of 2017-2025. The market was valued at $468.6 million in the year 2016 and the market worth is set to optimize up to $744.66 million by the end of 2025.
MARKET INSIGHTS
The European market is mainly driven by factors such as unhealthy eating habits, improved and efficient drugs in the pipeline and the easy availability of the drug in the European market. The segmentation of the market is done based on two criteria: drug type and prescription type. Lubiprostone drug is currently the most popular drug in the market. Also, the over the counter drug types are preferred over the branded and generic prescribed drugs. However, the unawareness and ignorance in the general populace regarding the drugs might restrict the market growth in the coming future.
COMPETITIVE INSIGHTS
Some of the major players in the market include:
- Astellas Pharmaceuticals
- Ardelyx, Inc.
- Synthetic Biologics, Inc.
- Teva Pharmaceutical Industries Limited
- Bama-Geve, Slu
- Ferring Bv
- Ironwood Pharmaceuticals, Inc.
1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM UP APPROACH
2.4. DATA TRIANGULATION
2.5. ESTIMATION METHODOLOGY
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
4. MARKET OVERVIEW
4.1. MARKET DEFINITION
4.2. KEY MARKET INSIGHTS
4.3. ATTRACTIVE INVESTMENT SCENARIO
4.4. POSITIONING OF KEY IBS DRUG MANUFACTURERS IN THE MARKET
4.5. DRIVERS
4.5.1. MODERN DIETARY HABITS TAKING TOLL ON THE HEALTH
4.5.2. PSYCHOLOGICAL FACTORS AFFECTING IRRITABLE BOWEL SYNDROME
4.5.3. IMPROVED AND EFFICIENT DRUGS IN PIPELINE WITH SEVERAL FIRST-IN-CLASS MOLECULES
4.5.4. IBS CAN BE A HERITABILITY ISSUE
4.5.5. AVAILABILITY OF EFFECTIVE DRUGS IN THE MARKET
4.6. RESTRAINTS
4.6.1. UNAWARENESS AND IGNORANCE AMONG PEOPLE
4.6.2. OPPORTUNITIES
4.6.3. INCREASING DEMAND FOR IBS DRUGS FROM APAC MARKET
4.6.4. HIGH UNMET NEEDS
4.7. CHALLENGES
4.7.1. CHANGE IN LIFESTYLE AND NATURAL WAYS TO CURE IBS
5. EUROPE IBS-C DRUG MARKET BY DRUG TYPE 2017-2025 ($ MILLION)
5.1. OVERVIEW
5.1.1. LUBIPROSTONE
5.1.2. LINACLOTIDE
5.1.3. STIMULANT LAXATIVES
5.1.4. OSMOTIC LAXATIVES
5.1.5. OTHERS (PSYLLIUM) – QUALITATIVE INFORMATION
5.2. PIPELINE DRUG ANALYSIS: PLECANATIDE (YEAR OF LAUNCH TO 2022, $ MILLION)
6. EUROPE IBS-C DRUG MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)
6.1. PRESCRIBED DRUGS
6.1.1. BRANDED IBS-C DRUGS MARKET 2017-2025 ($ MILLION)
6.1.2. GENERIC IBS-C DRUGS MARKET 2017-2025 ($ MILLION)
6.2. OVER THE COUNTER DRUGS
7. KEY ANALYTICS
7.1. PORTERS FIVE FORCE ANALYSIS
7.1.1. INTENSITY OF COMPETITIVE RIVALRYOMPETITION AMONG THE
7.1.2. BARGAINING POWER OF SUPPLIERS
7.1.3. BARGAINING POWER OF BUYERS
7.1.4. THREAT OF SUBSTITUTE PRODUCTS
7.1.5. THREAT OF NEW ENTRANTS
7.2. VENDOR LANDSCAPE
7.3. OPPORTUNITY MATRIX
8. EUROPE IBS-C DRUG MARKET BY COUNTRY 2017-2025 ($ MILLION)
8.1. UK
8.2. GERMANY
8.3. REST OF THE EUROPE
9. COMPANY PROFILES
9.1. CATALENT PHARMACEUTICALS SOLUTIONS
9.1.1. OVERVIEW
9.1.2. PRODUCT PORTFOLIO
9.1.3. SCOT ANALYSIS
9.1.4. STRATEGIC MOVES
9.2. NESTLE
9.2.1. OVERVIEW
9.2.2. PRODUCTS PORTFOLIO
9.2.3. SCOT ANALYSIS
9.2.4. STRATEGIC MOVES
9.3. ABBOTT LABORATORIES
9.3.1. OVERVIEW
9.3.2. PRODUCT PORTFOLIO
9.3.3. SCOT ANALYSIS
9.3.4. STRATEGIC MOVES
9.4. SYNERGY PHARMACEUTICALS
9.4.1. OVERVIEW
9.4.2. PRODUCTS PORTFOLIO
9.4.3. SCOT ANALYSIS
9.4.4. STRATEGIC MOVES
9.5. SUCAMPO PHARMACEUTICALS
9.5.1. OVERVIEW
9.5.2. PRODUCT PORTFOLIO
9.5.3. SCOT ANALYSIS
9.5.4. STRATEGIC MOVES
9.6. NOVARTIS PHARMA AG
9.6.1. OVERVIEW
9.6.2. PRODUCTS PORTFOLIO
9.6.3. SCOT ANALYSIS
9.6.4. STRATEGIC MOVES
9.7. ASTELLAS PHARMACEUTICALS
9.7.1. OVERVIEW
9.7.2. PRODUCT PORTFOLIO
9.7.3. SCOT ANALYSIS
9.7.4. STRATEGIC MOVES
9.8. ARDELYX, INC.
9.8.1. OVERVIEW
9.8.2. PRODUCT PORTFOLIO
9.8.3. SCOT ANALYSIS
9.8.4. STRATEGIC MOVES
9.9. SYNTHETIC BIOLOGICS, INC.
9.9.1. OVERVIEW
9.9.2. PRODUCT PORTFOLIO
9.9.3. SCOT ANALYSIS
9.9.4. STRATEGIC MOVES
9.10. TEVA PHARMACEUTICAL INDUSTRIES LIMITED
9.10.1. OVERVIEW
9.10.2. PRODUCT PORTFOLIO
9.10.3. SCOT ANALYSIS
9.10.4. STRATEGIC MOVES
9.11. BAMA-GEVE, SLU
9.11.1. OVERVIEW
9.11.2. PRODUCT PORTFOLIO
9.11.3. SCOT ANALYSIS
9.12. FERRING BV
9.12.1. OVERVIEW
9.12.2. PRODUCT PORTFOLIO
9.12.3. SCOT ANALYSIS
9.12.4. STRATEGIC MOVES
9.13. IRONWOOD PHARMACEUTICALS, INC.
9.13.1. OVERVIEW
9.13.2. PRODUCT PORTFOLIO
9.13.3. SCOT ANALYSIS
9.13.4. STRATEGIC MOVES
9.14. SALIX PHARMACEUTICALS LTD
9.14.1. OVERVIEW
9.14.2. PRODUCT PORTFOLIO
9.14.3. SCOT ANALYSIS
9.14.4. STRATEGIC MOVES
9.15. NORGINE B.V.
9.15.1. OVERVIEW
9.15.2. PRODUCT PORTFOLIO
9.15.3. SCOT ANALYSIS
9.15.4. STRATEGIC MOVES
9.16. PROMETHEUS LABORATORIES INC.
9.16.1. OVERVIEW
9.16.2. PRODUCT PORTFOLIO
9.16.3. SCOT ANALYSIS
9.16.4. STRATEGIC MOVES
9.17. ACTAVIS NORDIC A/S
9.17.1. OVERVIEW
9.17.2. PRODUCT PORTFOLIO
9.17.3. SCOT ANALYSIS
9.17.4. STRATEGIC MOVES
9.18. ALBIREO PHARMA INC
9.18.1. OVERVIEW
9.18.2. PRODUCT PORTFOLIO
9.18.3. SCOT ANALYSIS
9.18.4. STRATEGIC MOVES
9.19. YUHAN CORP
9.19.1. OVERVIEW
9.19.2. PRODUCT PORTFOLIO
9.19.3. SCOT ANALYSIS
9.19.4. STRATEGIC MOVES
9.20. ASTRAZENECA PLC
9.20.1. OVERVIEW
9.20.2. PRODUCT PORTFOLIO
9.20.3. SCOT ANALYSIS
9.20.4. STRATEGIC MOVES
9.21. THE MENARINI GROUP
9.21.1. OVERVIEW
9.21.2. PRODUCT PORTFOLIO
9.21.3. SCOT ANALYSIS
9.21.4. STRATEGIC MOVES
9.22. ONO PHARMACEUTICAL CO., LTD.
9.22.1. OVERVIEW
9.22.2. PRODUCT PORTFOLIO
9.22.3. SCOT ANALYSIS
9.22.4. STRATEGIC MOVES
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM UP APPROACH
2.4. DATA TRIANGULATION
2.5. ESTIMATION METHODOLOGY
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
4. MARKET OVERVIEW
4.1. MARKET DEFINITION
4.2. KEY MARKET INSIGHTS
4.3. ATTRACTIVE INVESTMENT SCENARIO
4.4. POSITIONING OF KEY IBS DRUG MANUFACTURERS IN THE MARKET
4.5. DRIVERS
4.5.1. MODERN DIETARY HABITS TAKING TOLL ON THE HEALTH
4.5.2. PSYCHOLOGICAL FACTORS AFFECTING IRRITABLE BOWEL SYNDROME
4.5.3. IMPROVED AND EFFICIENT DRUGS IN PIPELINE WITH SEVERAL FIRST-IN-CLASS MOLECULES
4.5.4. IBS CAN BE A HERITABILITY ISSUE
4.5.5. AVAILABILITY OF EFFECTIVE DRUGS IN THE MARKET
4.6. RESTRAINTS
4.6.1. UNAWARENESS AND IGNORANCE AMONG PEOPLE
4.6.2. OPPORTUNITIES
4.6.3. INCREASING DEMAND FOR IBS DRUGS FROM APAC MARKET
4.6.4. HIGH UNMET NEEDS
4.7. CHALLENGES
4.7.1. CHANGE IN LIFESTYLE AND NATURAL WAYS TO CURE IBS
5. EUROPE IBS-C DRUG MARKET BY DRUG TYPE 2017-2025 ($ MILLION)
5.1. OVERVIEW
5.1.1. LUBIPROSTONE
5.1.2. LINACLOTIDE
5.1.3. STIMULANT LAXATIVES
5.1.4. OSMOTIC LAXATIVES
5.1.5. OTHERS (PSYLLIUM) – QUALITATIVE INFORMATION
5.2. PIPELINE DRUG ANALYSIS: PLECANATIDE (YEAR OF LAUNCH TO 2022, $ MILLION)
6. EUROPE IBS-C DRUG MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)
6.1. PRESCRIBED DRUGS
6.1.1. BRANDED IBS-C DRUGS MARKET 2017-2025 ($ MILLION)
6.1.2. GENERIC IBS-C DRUGS MARKET 2017-2025 ($ MILLION)
6.2. OVER THE COUNTER DRUGS
7. KEY ANALYTICS
7.1. PORTERS FIVE FORCE ANALYSIS
7.1.1. INTENSITY OF COMPETITIVE RIVALRYOMPETITION AMONG THE
7.1.2. BARGAINING POWER OF SUPPLIERS
7.1.3. BARGAINING POWER OF BUYERS
7.1.4. THREAT OF SUBSTITUTE PRODUCTS
7.1.5. THREAT OF NEW ENTRANTS
7.2. VENDOR LANDSCAPE
7.3. OPPORTUNITY MATRIX
8. EUROPE IBS-C DRUG MARKET BY COUNTRY 2017-2025 ($ MILLION)
8.1. UK
8.2. GERMANY
8.3. REST OF THE EUROPE
9. COMPANY PROFILES
9.1. CATALENT PHARMACEUTICALS SOLUTIONS
9.1.1. OVERVIEW
9.1.2. PRODUCT PORTFOLIO
9.1.3. SCOT ANALYSIS
9.1.4. STRATEGIC MOVES
9.2. NESTLE
9.2.1. OVERVIEW
9.2.2. PRODUCTS PORTFOLIO
9.2.3. SCOT ANALYSIS
9.2.4. STRATEGIC MOVES
9.3. ABBOTT LABORATORIES
9.3.1. OVERVIEW
9.3.2. PRODUCT PORTFOLIO
9.3.3. SCOT ANALYSIS
9.3.4. STRATEGIC MOVES
9.4. SYNERGY PHARMACEUTICALS
9.4.1. OVERVIEW
9.4.2. PRODUCTS PORTFOLIO
9.4.3. SCOT ANALYSIS
9.4.4. STRATEGIC MOVES
9.5. SUCAMPO PHARMACEUTICALS
9.5.1. OVERVIEW
9.5.2. PRODUCT PORTFOLIO
9.5.3. SCOT ANALYSIS
9.5.4. STRATEGIC MOVES
9.6. NOVARTIS PHARMA AG
9.6.1. OVERVIEW
9.6.2. PRODUCTS PORTFOLIO
9.6.3. SCOT ANALYSIS
9.6.4. STRATEGIC MOVES
9.7. ASTELLAS PHARMACEUTICALS
9.7.1. OVERVIEW
9.7.2. PRODUCT PORTFOLIO
9.7.3. SCOT ANALYSIS
9.7.4. STRATEGIC MOVES
9.8. ARDELYX, INC.
9.8.1. OVERVIEW
9.8.2. PRODUCT PORTFOLIO
9.8.3. SCOT ANALYSIS
9.8.4. STRATEGIC MOVES
9.9. SYNTHETIC BIOLOGICS, INC.
9.9.1. OVERVIEW
9.9.2. PRODUCT PORTFOLIO
9.9.3. SCOT ANALYSIS
9.9.4. STRATEGIC MOVES
9.10. TEVA PHARMACEUTICAL INDUSTRIES LIMITED
9.10.1. OVERVIEW
9.10.2. PRODUCT PORTFOLIO
9.10.3. SCOT ANALYSIS
9.10.4. STRATEGIC MOVES
9.11. BAMA-GEVE, SLU
9.11.1. OVERVIEW
9.11.2. PRODUCT PORTFOLIO
9.11.3. SCOT ANALYSIS
9.12. FERRING BV
9.12.1. OVERVIEW
9.12.2. PRODUCT PORTFOLIO
9.12.3. SCOT ANALYSIS
9.12.4. STRATEGIC MOVES
9.13. IRONWOOD PHARMACEUTICALS, INC.
9.13.1. OVERVIEW
9.13.2. PRODUCT PORTFOLIO
9.13.3. SCOT ANALYSIS
9.13.4. STRATEGIC MOVES
9.14. SALIX PHARMACEUTICALS LTD
9.14.1. OVERVIEW
9.14.2. PRODUCT PORTFOLIO
9.14.3. SCOT ANALYSIS
9.14.4. STRATEGIC MOVES
9.15. NORGINE B.V.
9.15.1. OVERVIEW
9.15.2. PRODUCT PORTFOLIO
9.15.3. SCOT ANALYSIS
9.15.4. STRATEGIC MOVES
9.16. PROMETHEUS LABORATORIES INC.
9.16.1. OVERVIEW
9.16.2. PRODUCT PORTFOLIO
9.16.3. SCOT ANALYSIS
9.16.4. STRATEGIC MOVES
9.17. ACTAVIS NORDIC A/S
9.17.1. OVERVIEW
9.17.2. PRODUCT PORTFOLIO
9.17.3. SCOT ANALYSIS
9.17.4. STRATEGIC MOVES
9.18. ALBIREO PHARMA INC
9.18.1. OVERVIEW
9.18.2. PRODUCT PORTFOLIO
9.18.3. SCOT ANALYSIS
9.18.4. STRATEGIC MOVES
9.19. YUHAN CORP
9.19.1. OVERVIEW
9.19.2. PRODUCT PORTFOLIO
9.19.3. SCOT ANALYSIS
9.19.4. STRATEGIC MOVES
9.20. ASTRAZENECA PLC
9.20.1. OVERVIEW
9.20.2. PRODUCT PORTFOLIO
9.20.3. SCOT ANALYSIS
9.20.4. STRATEGIC MOVES
9.21. THE MENARINI GROUP
9.21.1. OVERVIEW
9.21.2. PRODUCT PORTFOLIO
9.21.3. SCOT ANALYSIS
9.21.4. STRATEGIC MOVES
9.22. ONO PHARMACEUTICAL CO., LTD.
9.22.1. OVERVIEW
9.22.2. PRODUCT PORTFOLIO
9.22.3. SCOT ANALYSIS
9.22.4. STRATEGIC MOVES
LIST OF TABLES
TABLE 1 EUROPE IBS-C MARKET BY COUNTRY 2017-2025 ($ MILLION)
TABLE 2 WELL KNOWN DRUGS THAT ARE PREVALENT IN IBS TREATMENT DRUG MARKET ARE
TABLE 3 IRRITABLE BOWEL SYNDROME DRUGS
TABLE 4 EUROPE IBS-C DRUGS MARKET BY DRUG TYPE, 2017-2025 ($ MILLION)
TABLE 5 PRODUCT PROFILE (LUBIPROSTONE)
TABLE 6 PRODUCT PROFILE (LINACLOTIDE)
TABLE 7 PRODUCT PROFILE (BISACODYL)
TABLE 8 PRODUCT PROFILE (SENNA)
TABLE 9 PRODUCT PROFILE (LACTULOSE)
TABLE 10 PRODUCT PROFILE (POLYETHYLENE GLYCOL)
TABLE 11 PRODUCT PROFILE (PSYLLIUM)
TABLE 12 PIPELINE PRODUCT PROFILE (PLECANATIDE)
TABLE 13 EUROPE IBS-C DRUGS MARKET, BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)
TABLE 14 PRODUCT PROFILE (LUBIPROSTONE)
TABLE 15 PRODUCT PROFILE (METHYL NALTREXONE BROMIDE)
TABLE 16 PRODUCT PROFILE (METAMUCIL)
TABLE 17 EUROPE IBS-C DRUG MARKET BY COUNTRY 2017-2025 ($ MILLION)
TABLE 1 EUROPE IBS-C MARKET BY COUNTRY 2017-2025 ($ MILLION)
TABLE 2 WELL KNOWN DRUGS THAT ARE PREVALENT IN IBS TREATMENT DRUG MARKET ARE
TABLE 3 IRRITABLE BOWEL SYNDROME DRUGS
TABLE 4 EUROPE IBS-C DRUGS MARKET BY DRUG TYPE, 2017-2025 ($ MILLION)
TABLE 5 PRODUCT PROFILE (LUBIPROSTONE)
TABLE 6 PRODUCT PROFILE (LINACLOTIDE)
TABLE 7 PRODUCT PROFILE (BISACODYL)
TABLE 8 PRODUCT PROFILE (SENNA)
TABLE 9 PRODUCT PROFILE (LACTULOSE)
TABLE 10 PRODUCT PROFILE (POLYETHYLENE GLYCOL)
TABLE 11 PRODUCT PROFILE (PSYLLIUM)
TABLE 12 PIPELINE PRODUCT PROFILE (PLECANATIDE)
TABLE 13 EUROPE IBS-C DRUGS MARKET, BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)
TABLE 14 PRODUCT PROFILE (LUBIPROSTONE)
TABLE 15 PRODUCT PROFILE (METHYL NALTREXONE BROMIDE)
TABLE 16 PRODUCT PROFILE (METAMUCIL)
TABLE 17 EUROPE IBS-C DRUG MARKET BY COUNTRY 2017-2025 ($ MILLION)
LIST OF FIGURES
FIGURE 1 EUROPE IBS-C DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 2 EUROPE IBS-C DRUG MARKET BY DRUG TYPE 2016 & 2025 (%)
FIGURE 3 EUROPE IBS-C DRUG MARKET BY PRESCRIPTION TYPE 2016 (%)
FIGURE 4 DIETS RESPONSIBLE FOR IBS
FIGURE 5 DRUGS PULLED OFF FROM THE MARKET
FIGURE 6 LIFESTYLE AND HOME REMEDIES FOR IBS
FIGURE 7 UK IBS-C DRUG MARKET, 2017-2025 ($ MILLION)
FIGURE 8 GERMANY IBS-C DRUGS MARKET, 2017-2025, ($ MILLION)
FIGURE 9 REST OF EUROPE IBS-C DRUGS MARKET, 2017-2025, ($ MILLION)
FIGURE 1 EUROPE IBS-C DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 2 EUROPE IBS-C DRUG MARKET BY DRUG TYPE 2016 & 2025 (%)
FIGURE 3 EUROPE IBS-C DRUG MARKET BY PRESCRIPTION TYPE 2016 (%)
FIGURE 4 DIETS RESPONSIBLE FOR IBS
FIGURE 5 DRUGS PULLED OFF FROM THE MARKET
FIGURE 6 LIFESTYLE AND HOME REMEDIES FOR IBS
FIGURE 7 UK IBS-C DRUG MARKET, 2017-2025 ($ MILLION)
FIGURE 8 GERMANY IBS-C DRUGS MARKET, 2017-2025, ($ MILLION)
FIGURE 9 REST OF EUROPE IBS-C DRUGS MARKET, 2017-2025, ($ MILLION)
